Finally, to test the possible therapeutic utility of pharmacologic inhibition of the Cxcl12/Cxcr4 axis on antral tumor development, we treated Mist1-CreERT; Cxcr4-EGFP; Apcflox/flox mice with AMD3100, a specific inhibitor of CXCR4. This evidence concerns the gene CXCL12 and neoplasm.